Calcium phosphate biomaterials as bone drug delivery systems: A review

Drug Discovery Today

Volumn 15, Issue 13-14, 2010, Pages 547-552

  Verron, Elise ^a,b   Khairoun, Ibrahim ^a   Guicheux, Jerome ^a   Bouler, Jean Michel ^a  

^a Universite de Nantes   (France)

^b Graftys SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; BONE MORPHOGENETIC PROTEIN; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE CERAMIC; CEMENT; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA;

BONE INFECTION; BONE PROSTHESIS; BONE REGENERATION; BONE REMODELING; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; OSTEOPOROSIS; REVIEW;

ANIMALS; BONE AND BONES; CALCIUM PHOSPHATES; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 77954313439     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.05.003     Document Type: Review

References (70)

1. Fogueri L.R., Singh S. Smart polymers for controlled delivery of proteins and peptides: a review of patents. Recent Pat. Drug Deliv. Formul. 2009, 3:40-48.
2. Quintanar-Guerrero D., et al. Silica xerogels as pharmaceutical drug carriers. Expert Opin. Drug Deliv. 2009, 6:485-498.
3. Rush S.M. Bone graft substitutes: osteobiologics. Clin. Podiatr. Med. Surg. 2005, 22:619-630.
4. Vallet-Regí M. Revisiting ceramics for medical applications. Dalton Trans. 2006, 28:5211-5220.
5. LeGeros R.Z. Calcium phosphate in oral biology and medicine. Monogr. Oral Sci. 1991, 15:1-201.
6. Daculsi G., et al. Adaptive crystal formation in normal and pathological calcifications in synthetic calcium phosphate and related biomaterials. Int. Rev. Cytol. 1997, 172:129-191.
7. Gauthier O., et al. Macroporous biphasic calcium phosphate ceramics: influence of macropore diameter and macroporosity percentage on bone ingrowth. Biomaterials 1998, 19:133-139.
8. Bouler J.M., et al. Macroporous biphasic calcium phosphate ceramics: influence of five synthesis parameters on compressive strength. J. Biomed. Mater. Res. 1996, 32:603-609.
9. Ooms E.M., et al. Histological evaluation of the bone response to calcium phosphate cement implanted in cortical bone. Biomaterials 2003, 24:989-1000.
10. Williams D.F. On the mechanisms of biocompatibility. Biomaterials 2008, 29:2941-2953.
11. Minkin C., Marinho V.C. Role of the osteoclast at the bone-implant interface. Adv. Dent. Res. 1999, 13:49-56.
12. Detsch R., et al. Formation of osteoclast-like cells on HA and TCP ceramics. Acta Biomater. 2008, 4:139-148.
13. Parikh S. Bone graft substitutes in modern orthopedics. Orthopedics 2002, 25:1301-1310.
14. LeGeros R.Z. Properties of osteoconductive biomaterials: calcium phosphates. Clin. Orthop. Relat. Res. 2002, 395:81-98.
15. Brown W.E., Chow L.C. Effects of neutral salts in a bench-scale caries model. J. Dent. Res. 1986, 65:1115-1120.
16. Khairoun I., et al. Effect of calcium carbonate on the compliance of an apatitic calcium phosphate bone cement. Biomaterials 1997, 18:1535-1539.
17. Khairoun I., et al. In vitro characterization and in vivo properties of a carbonated apatite bone cement. J. Biomed. Mater. Res. 2002, 60:633-642.
18. Sugawara A., et al. Histopathological and cell enzyme studies of calcium phosphate cements. Dent. Mater. J. 2004, 23:613-620.
19. Smartt J.M., et al. Repair of the immature and mature craniofacial skeleton with a carbonated calcium phosphate cement: assessment of biocompatibility, osteoconductivity, and remodeling capacity. Plast. Reconstr. Surg. 2005, 115:1642-1650.
20. Xu H.H., et al. Fast-setting calcium phosphate scaffolds with tailored macropore formation rates for bone regeneration. J. Biomed. Mater. Res. A 2004, 68:725-734.
21. Weir M.D., Xu H.H. High-strength, in situ-setting calcium phosphate composite with protein release. J. Biomed. Mater. Res. A 2008, 85:388-396.
22. Xu H.H., Quinn J.B. Calcium phosphate cement containing resorbable fibers for short-term reinforcement and macroporosity. Biomaterials 2002, 23:193-202.
23. Ginebra M.P., et al. Calcium phosphate cements as bone drug delivery systems: a review. J. Control. Release 2006, 113:102-110.
24. Kanczler J.M., Oreffo R.O. Osteogenesis and angiogenesis: the potential for engineering bone. Eur. Cell. Mater. 2008, 15:100-114.
25. Lee S.H. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv. Drug Deliv. Rev. 2007, 30:339-359.
26. Okubo Y., et al. Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites. Int. J. Oral Maxillofac. Surg. 2000, 29:62-66.
27. Seeherman H.J., et al. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate model. J. Bone Joint Surg. Am. 2004, 86-A:1961-1972.
28. Seeherman H.J., et al. rhBMP-2 delivered in a calcium phosphate cement accelerates bridging of critical-sized defects in rabbit radii. J. Bone Joint Surg. Am. 2006, 88:1553-1565.
29. Sumner D.R., et al. Locally delivered rhTGF-beta2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury. J. Orthop. Res. 2001, 19:85-94.
30. Haddad A.J., et al. Closure of rabbit calvarial critical-sized defects using protective composite allogeneic and alloplastic bone substitutes. J. Craniofac. Surg. 2006, 17:926-934.
31. Guicheux J., et al. Human growth hormone locally released in bone sites by calcium-phosphate biomaterial stimulates ceramic bone substitution without systemic effects: a rabbit study. J. Bone Miner. Res. 1998, 13:739-748.
32. Namikawa T., et al. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and beta-tricalcium phosphate in a rabbit model. Spine 2005, 30:1717-1722.
33. Dimar J.R., et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 2006, 31:2534-2539.
34. Blom E.J., et al. Transforming growth factor-beta1 incorporated in calcium phosphate cement stimulates osteotransductivity in rat calvarial bone defects. Clin. Oral Implants Res. 2001, 12:609-616.
35. Luginbuehl V., et al. Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration. Pharm. Res. 2005, 22:940-950.
36. Josse S., et al. An innovative strategy for local treatment of bone resorption and prevention of osteoporotic fractures. Adv. Mater. 2004, 16:1423-1427.
37. Josse S., et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005, 26:2073-2080.
38. Roussière H., et al. Reaction of zoledronate with β-tricalcium phosphate for the design of potential drug device combined systems. Chem. Mater. 2008, 20:182-191.
39. Denissen H., et al. Ceramic hydroxyapatite implants for the release of biphosphonate. Bone Miner. 1994, 25:123-134.
40. Seshima H., et al. Control of bisphosphonate release using hydroxyapatite granules. J. Biomed. Mater. Res. B Appl. Biomater. 2006, 78:215-221.
41. Boanini E., et al. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 2008, 29:790-796.
42. Panzavolta S., et al. Alendronate and pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J. Inorg. Biochem. 2009, 103:101-106.
43. Yayon, A. (2004) Bone enhancing composite. Patent N° WO2004043333.
44. Dorozhkin S.V., Epple M. Biological and medical significance of calcium phosphates. Angew. Chem. Int. Ed. Engl. 2002, 41:3130-3146.
45. Roussière H., et al. Hybrid materials applied to biotechnologies: coating of calcium phosphates for the design of implants active against bone resorption. J. Mater. Chem. 2005, 15:3869-3875.
46. Faucheux C., et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J. Biomed. Mater. Res. A 2009, 89:46-56.
47. Grimandi G., et al. Quantitative and reliable in vitro method combining scanning electron microscopy and image analysis for the screening of osteotropic modulators. Microsc. Res. Tech. 2006, 69:606-612.
48. Peter B., et al. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J. Biomed. Mater. Res. A 2006, 76:133-143.
49. Peter B., et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 2005, 36:52-60.
50. Shi X., et al. Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications. Pharm. Res. 2009, 26:422-430.
51. Wang C.J., et al. The often poor clinical outcome of infected total knee arthroplasty. J. Arthroplasty 2002, 17:608-614.
52. Saleh K., et al. Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. J. Orthop. Res. 2002, 20:506-515.
53. Sudo A., et al. Treatment of infected hip arthroplasty with antibiotic-impregnated calcium hydroxyapatite. J. Arthroplasty 2008, 23:145-150.
54. Jacobs A.M., et al. Use of antibiotic-loaded bone cement in the management of common infections of the foot and ankle. Clin. Podiatr. Med. Surg. 1990, 7:523-544.
55. Youngman J.R., et al. Antibiotic-loaded cement in revision joint replacement. Hosp. Med. 2003, 64:613-616.
56. Diefenbeck M., et al. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury 2006, 37(Suppl. 2):S95-S104.
57. Parvizi J., et al. Efficacy of antibiotic-impregnated cement in total hip replacement. Acta Orthop. 2008, 79:335-341.
58. van de Belt H., et al. Staphylococcus aureus biofilm formation on different gentamicin-loaded polymethylmethacrylate bone cements. Biomaterials 2001, 22:1607-1611.
59. Joseph T.N., et al. Use of antibiotic-impregnated cement in total joint arthroplasty. J. Am. Acad. Orthop. Surg. 2003, 11:38-47.
60. Neut D., et al. Pseudomonas aeruginosa biofilm formation and slime excretion on antibiotic-loaded bone cement. Acta Orthop. 2005, 76:109-114.
61. Bacci G., et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop. Scand. 2003, 74:449-454.
62. Federman N., et al. The multidisciplinary management of osteosarcoma. Curr. Treat. Options Oncol. 2009, 10:82-93.
63. Turcotte R.E., et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin. Orthop. Relat. Res. 2002, 248-258.
64. Abe T., et al. Intraosseous delivery of paclitaxel-loaded hydroxyapatitealginate composite beads delaying paralysis caused by metastatic spine cancer in rats. J. Neurosurg. Spine 2008, 9:502-510.
65. Itokazu M., et al. Development of porous apatite ceramic for local delivery of chemotherapeutic agents. J. Biomed. Mater. Res. 1998, 39:536-538.
66. Itokazu M., et al. Local drug delivery system using ceramics: vacuum method for impregnating a chemotherapeutic agent into a porous hydroxyapatite block. J. Mater. Sci. Mater. Med. 1999, 10:249-252.
67. Guicheux J., et al. Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: an in vitro study. Bone 1998, 22:25-31.
68. Deckers M.M., et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 2002, 143:1545-1553.
69. Kim I.Y., et al. Transforming growth factor-beta: biology and clinical relevance. J. Biochem. Mol. Biol. 2005, 38:1-8.
70. Matsuda N., et al. Mitogenic, chemotactic, and synthetic responses of rat periodontal ligament fibroblastic cells to polypeptide growth factors in vitro. J. Periodontol. 1992, 63:515-525.